LOXL2 and osteosarcoma: In vitro experiments confirmed that treatment of osteosarcoma cells with FGF-23 increased LOXL2 mRNA and protein expression in a dose-dependent manner, while the effects on LOXL1 and LOXL3 were comparatively limited.